ClinicalTrials.gov
public full text
Public Domain
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
This is a non-randomized phase 1 trial designed to determine the MTD and evaluate the safety and tolerability of ACY-1215 with nab-paclitaxel. Based on the activity profile of ACY-1215 in breast cancer, corresponding biomarker availability with the HDAC6 MR score, and its potential synergy with taxanes, these data support the rationale for testing the ability of ACY-1215 to improve the response rate for patients with metastatic breast cancer in combination with standard taxane chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy#860989
- A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.#1138221
- Capecitabine in Women With Operable Breast Cancer#1057153
- ModraDoc006/r in Patients With Breast Cancer#826283
- A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC#900442
Record · ID 1032845
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive